The startup creates monoclonal antibodies for treating solid and hematological malignancies by targeting members of the Nectin family of receptors and ligands that play a significant role in immune checkpoint mechanisms relevant to cancer immunotherapy. These innovative antibodies have the potential to improve the lives of patients and cure them, providing healthcare providers with a new tool to combat cancer.